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Cryptosporidium oocysts, observed in a natural spu-
tum sample of a patient with HIV, were further studied by
using DNA markers to determine the species of the para-
site. C. hominis was identified as the species infecting the
patient’s respiratory tract, a finding that strengthens evi-
dence regarding this pathogen’s role in human disease.
I
ntestinal cryptosporidiosis is a common parasitic disease
that causes self-limiting diarrhea in immunocompetent
persons (1). Higher frequencies of Cryptosporidium infec-
tion are observed in immunocompromised humans, and
the main clinical pattern of the infection in these persons is
a chronic, life-threatening secretory diarrhea (2).
At least 8 species of Cryptosporidium are described as
infecting humans. C. hominis and C. parvum are the most
frequently observed in intestinal infections in humans (3).
C. meleagridis is also detected both in immunocompetent
and immunodeficient patients, although at a lower rate
than C. parvum (4).
Respiratory tract infection by Cryptosporidium spp.
has been described for immunodeficient persons, most all
of whom were coinfected with HIV. However, pulmonary
cryptosporidiosis was also described in patients without
HIV infection (5,6). In all cases, no systematic identifica-
tion of the species of Cryptosporidium was pursued except
by Meamar et al. (7), in which the parasite was identified
as C. parvum.
We describe the detection and identification of C.
hominis in the respiratory secretions of a patient with HIV
(sample Chile01). We used an oligonucleotide species-spe-
cific method and sequencing of parts of the 18S rRNAgene
to determine the species of Cryptosporidium. Both analyses
showed that the species of Cryptosporidium present in the
pulmonary secretion of this patient was C. hominis.
The Study
In September 2004, a 58-year-old man, who received
an HIV-positive diagnosis in 1996, was hospitalized with
respiratory symptoms characterized by persistent cough.
Cryptosporidium oocysts were detected in a sputum sam-
ple from the patient by using Ziehl-Neelsen stain
(Figure 1). An aliquot of ≈10 mL of respiratory secretion
was obtained. DNAwas extracted as follows: 200 µL fluid
was centrifuged and the pelleted material digested
overnight at 65ºC with proteinase K in the presence of
10% sodium dodecyl sulfate. We then sequentially
extracted the digested material with phenol, phenol-
chloroform-isoamyl alcohol, and chloroform-isoamyl
alcohol. The DNA was then precipitated with sodium
acetate and ethanol, and after centrifugation, the pelleted
DNA was dissolved in 50 µL of water.
For molecular typing, we first used the species-specif-
ic oligonucleotide PCR assay Lib13, as described by
Tanriverdi et al. (8), with a new sense oligonucleotide
primer based on the genome sequences of C. hominis (9)
and  C. parvum (10). The new primer, Lib13SF02 (5′-
TTTTTTCATTAGCTCGCTTC-3′), a fragment of ≈400
bp, was amplified specifically from C. hominis DNA with
the anti-sense primers Lib13SRT-1 (5′-ATTTATTAATTTA
TCTCTTACTT-3′) and from C. parvum DNA with Lib13
SRT-2 (5′-ATTTATTAATTTATCTCTTCG-3′) (Figure 2).
Amplifications were carried out in a PCR mixture of 10 µL
containing 0.25 mmol/Lof each dNTP, 300 pmol/Lof each
olignucleotide, and 1 unit of Taq DNA polymerase
(HotMaster, Eppendorf, New York, NY, USA).
Temperature cycling was performed on a GeneAmp PCR
System (ABI, Foster City, CA, USA) with initial denatura-
tion performed at 95ºC for 5 min, then 40 cycles at 95ºC
for 30 s, 52ºC for 30 s, and 68ºC for 30 s. The mixture was
then cooled to 4ºC.
The region from bases 7 to 1036 (numbering accord-
ing to C. hominis sequence GenBank no. L16996) of the
18S rRNA gene was sequenced from DNA fragments
amplified using the primers 18SF (5′-GTTGATCCT
GCCAGTAGTC-3′) and 18SR (5′-TAAGGTGCTGAAG
GAGTAAGG-3′) and cloned into the TOPO TA vector
(Invitrogen, Brandford, CT, USA) by using standard tech-
niques. Automated sequencing was performed directly on
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Figure 1. Oocysts (arrows), stained by using the Ziehl-Neelsen
method, in sputum from the patient with HIV. the amplified fragments or on cloned fragments at the
Nucleic Acid Research Facilities of Virginia
Commonwealth University. All DNA sequences were ana-
lyzed by using Sequencher (Gene Codes Co., Ann Arbor,
MI, USA).
Figure 1 shows fuchsia (Ziehl-Neelsen)–stained spu-
tum from the patient. Three Cryptosporidium oocysts
(arrows) with typical sizes ≈5 µm in diameter are visible.
Measurements were performed in a calibrated microscope
as described by Mercado and Santander (11).
A Lib13 PCR assay (8) was performed on the DNA
purified from the respiratory secretion material, and the
results are shown in Figure 2. With the C. hominis specif-
ic-primer pair (LIBF02/Lib13SRT1), a fragment of the
expected size (≈400 bp) was amplified with the Chile01
isolate DNA (Figure 2, lane 2). With this primer pair, we
also obtained amplification with the C. hominis isolate
TU502 (12) DNA (Figure 2, lane 3) but not with the C.
parvum isolate Moredun (13) DNA (Figure 2, lane 4).
Conversely, the C. parvum–specific primer pair
(LIBF02/Lib13SRT2) amplified a fragment only with the
C. parvum DNA (Figure 2, lane 8). No amplification was
observed with the Chile01 (Figure 2, lane 6) or the C.
hominis DNA (Figure 2, lane 7). DNA sequencing of the
amplified fragments confirmed the polymorphism to be
that of C. hominis (results not shown).
We also analyzed the 18S small subunit rRNAgene by
amplifying and sequencing an 18S rRNA fragment from
the sputum DNA. Amplification and sequencing was con-
comitantly performed with the C. hominis and C. parvum
DNA. A polymorphic site exists in C. hominis as a stretch
of 10 to 12 thymines (T10–12), while in C. parvum, the
sequence is TA:::TATATTTT (14). The 18S rRNA poly-
morphic sequence found in the sputum sample DNA
(GenBank accession no. DQ286403) is that of C. hominis,
with a stretch of 11 Ts (Table). Few other nucleotide poly-
morphisms were found between the sequences (results not
shown), which reflect intraisolate variations (14). The
results with Lib13 assay and the partial 18S rRNA
sequence analysis, therefore, identify the species of
Cryptosporidium infecting the respiratory tract of this
patient as C. hominis.
Conclusions
Human cryptosporidiosis is better known as an intes-
tinal disease both in immunocompetent and immunocom-
promised persons. Little information exists, however, on
human pulmonary disease caused by Cryptosporidium
spp., which reflects either the low prevalence of pul-
monary cryptosporidiosis or the lack of testing in immuno-
competent hosts. Further, if performed, current diagnostic
tests may not be sensitive enough to detect the parasite. 
In immunocompetent children with intestinal cryp-
tosporidiosis, respiratory symptoms have been noted more
frequently than expected (5). Studies are needed in
immunocompetent persons, especially children <2 years of
age, who belong to a group at high risk for intestinal, and
by extension pulmonary, cryptosporidiosis.
More information about which species of this
pathogen infect humans and the pathogenic patterns each
species produces is needed. As we determined here, C.
hominis have the capacity to adapt to different physiolog-
ic environments, such as intestinal and respiratory tract tis-
sues. Our findings provide additional evidence supporting
the role of this species of Cryptosporidium as a human
pathogen and the need to evaluate the importance of pul-
monary cryptosporidiosis as a disease in the immunocom-
promised host.
Acknowledgments
We thank Giovanni Widmer and Sultan Tanriverdi for the
C. parvum DNA and helpful discussions and Carmen Chambel,
Claudio Rojas, and Sergio Guillermo Tula for technical assistance. 
C. hominis in Human Respiratory Tract
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 3, March 2007 463
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